SHPGF Stock DD Shire Plc. 08/11/2014 22:38:04

New Post Public Reply Private Reply Replies (0) Message Board

Aug 11, 2014 at 11:38 PM

SHPGF Shire Plc. $SHPGF Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=SHPGF&am...mp;yt0=Go!

Last Updated: 08/11/2014 22:38:00

Current Price and Quotes
Last Price 79.15
Previous Close 77.85 Open 78.80
Daily Range N/A - 79.90 52wk Range 36.55 - 85.90
Volume 1,304 Dividend N/A
Average Vol (30d) 13,402 Yield N/A

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 4,934,300 4,527,400 4,158,100 3,471,100
Cost of Revenue 670,800 585,800 551,700 463,400
Gross Profit 4,263,500 3,941,600 3,606,400 3,007,700
Operating Expenses

Research and Development 933,400 953,000 764,500 661,500
Sales, General and Admin. 1,651,300 1,948,000 1,675,700 1,526,300
Non-Recurring Items (38,800) 13,500 24,400 42,300
Other - - - -
Operating Income 1,733,500 1,045,200 1,135,800 794,100
Income From Continuing Operations

Add'l Income/Expense Items 14,100 18,900 14,400 26,800
Earnings Before Interest and Tax 1,731,700 1,046,000 1,156,200 804,400
Interest Expense 38,100 38,200 39,100 35,100
Earnings Before Tax 1,693,600 1,007,800 1,117,100 769,300
Income Tax 277,900 203,100 236,900 182,700
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary 3,900 1,000 2,500 1,400
Net Income Cont. Operations 1,419,600 805,700 882,700 588,000
Non Recurring Events

Discontinued Operations (754,500) (60,300) (17,700) -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 665,100 745,400 865,000 588,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 665,100 745,400 865,000 588,000

Recent News

Aug 1, 2014 ANI Pharmaceuticals Acquires Vancocin® Capsules and Additional Vancomycin Assets from Shire
Jul 30, 2014 Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Jul 29, 2014 Shire Announces Award Recipients for 2014 Michael Yasick ADHD Scholarship
Jul 23, 2014 Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Jul 23, 2014 ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome
Jul 18, 2014 Critical Alerts For Shire, Whole Foods Market, NVIDIA, Rockwell Medical, and Coca-Cola Released By InvestorsObserver
Jul 18, 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Jul 18, 2014 Shire Delivers Record Quarterly Revenues and Non GAAP Diluted Earnings per ADS up 42%
Jul 18, 2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Jul 18, 2014 Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

1
2
3
next >

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wendy's Faces Takeover Bid Amid Strategic Focus Shift

Behind the Unsolicited Offer Folks, it looks like Wendy's (NASDAQ:WEN) got itself mixed up in some high-stakes shenanigans. An unsolicited, non-binding proposal slammed into them, courtesy of the Investor Group led by Trian Partners, Flynn Group LP, BlueFive Capital, and Sixth Street Partners, itching to scoop up every last piece of Wendy’s stock they ain't already...

Beta Bionics: Investors on Edge, Legal Moves Underway

A Tumultuous Time for Beta Bionics Investors Trouble's brewing for those holding Beta Bionics, Inc. (NASDAQ: BBNX) shares. This isn't just market jitters—it's a full-blown legal tussle. The shareholder-rights law honchos at Johnson Fistel are sounding the alarms, and investors better heed their call before the clock strikes November 3, 2026. There's a class action...

Personalized Senior Living Guidance Finds Home in South Jersey

Shaunique Adams and Her Mission in South Jersey In a world where compassion sometimes feels like it's on short supply, Shaunique Adams is making sure it's at the forefront of her mission. Having experienced the emotional whirlwind of caregiving firsthand, Adams has transformed her personal journey into a mission to serve families navigating similar paths. Through Trua...

Northeast Indiana Bancorp Shows Solid Third Quarter Gains

Holding Steady in a Shaky Market In a market often rocked by turbulence, it seems Northeast Indiana Bancorp, Inc. has found a decent footing to stand on. Announcing their third-quarter results for 2026, they’ve posted net income of $1.991 million, showcasing a neat jump from the $1.793 million in the same period last year. Not bad at all for the parent company of First...

Air Canada-CAE Scholarship Drives Women in Aviation

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

Beta Bionics Faces Securities Fraud Class Action Challenges

The Unexpected Slide of Beta Bionics So your wallet took a bruising with this Beta Bionics deal, eh? It’s another one of those wild tales from the stock jungle where everyone watching the NASDAQ:BBNX action got clipped when reality didn't match the company chest-thumping. Glancy Prongay Wolke & Rotter LLP just laid it out—ripping the Band-Aid off what Beta Bionics...

Fannie Mae Q3 2026 Earnings Surpass Expectations

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Regal Healthcare: Five Years of Founder-Friendly Valor

Why Founder-Friendly Matters More Than Ever in Healthcare Well folks, in a year when everyone's tossing around terms like 'value-added' and 'strategic support', seeing Regal Healthcare Capital Partners snag slot number five straight on Inc.'s Founder-Friendly Investors list feels like catching a rare breed of fish twice. Seriously, these folks are stamping their forte as...

2021 Ferrari Portofino Shines Bright at Jake's Motorcars

San Diego might be known for its sunny weather, but Jake's Motorcars just cranked the heat with a 2021 Ferrari Portofino that flaunts a special-ordered Mandarin Orange interior. Now, if that doesn't scream "look at me," I don't know what does. For those who aren't just dabbling in Ferraris but are downright obsessed, let's dig into what makes this sports car not just...

Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...